Opinion|Videos|August 5, 2024
Third-line Treatment Options for DLBCL After CAR T-cell Therapy or ASCT in Second-line
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please give an overview of treatment options for a patient who received 2L treatment with either CAR T-cell therapy or ASCT and has relapsed.
- What would be your treatment choice in the third line?
- What key issues do you consider in your sequencing decisions?
- Please discuss rationales for each:
- Monoclonal antibody—tafasitamab?
- ADC —loncastuximab, polatuzumab?
- Would you go to CAR T after ASCT?
- Bispecific antibody—epcoritamab or glofitamab?
Advertisement
Related to this article
Experts break down key melanoma data and trends from the 2026 ESMO Congress.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Experts break down key kidney cancer data and trends from the 2026 ESMO Congress.
Durvalumab plus BCG is now an approved first-line option for high-risk NMIBC, but better BCG delivery and biomarker-guided selection should shape its use.
The FDA has approved amivantamab and hyaluronidase-lpuj for metastatic head and neck squamous cell carcinoma.
A UCLA-led study suggests routine mammograms or other breast imaging may not benefit women after double mastectomy for DCIS.
Experts break down key gynecologic cancer data and trends from the 2026 ESMO Congress.
Are we ready to “take that fork in the road” and move palliative/supportive care into routine cancer care?
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Amivantamab and Hyaluronidase for Metastatic HNSCC
2
BCG Optimization Becomes a Priority as Durvalumab Gains a Role in High-Risk NMIBC
3
Dr Cai on the Rationale for Evaluating Rocbrutinib Plus R-CHOP in Non-GCB DLBCL and MCL
4
Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC
5